Research that resulted in FDA approval for semaglutide as a weight loss medication found that people could lose 15% to 20% of their total weight
GLP-1 is an incretin released after eating, and the article says it signals fullness, slows gastric emptying and promotes insulin secretion in response to blood glucose
Stay at the current dose until GI symptoms have resolved for at least two full weeks
Gallstones, inflammation, or other gallbladder problems may cause symptoms such as severe abdominal pain, nausea, vomiting, and bloating
Baseline Metabolic Status: Are your research subjects metabolically healthy, or are they models of obesity, insulin resistance, or diabetes